Bye Bye Prolia Reps

Discussion in 'Amgen' started by Anonymous, Mar 29, 2011 at 8:41 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    March 27, 2011

    Goldman Sachs
    Amgen Analyst Day Preview

    "In our view, cost cuts are probable and could give Amgen some leverage. We think the cost cut is more likely in SG&A than in R&D. The SG&A cut would likely depend on how much Amgen continues to invest in the denosumab franchise (especially Prolia, where the expenses are more meaningful, as it is targeting a primary care market)."
     

  2. Anonymous

    Anonymous Guest

    Good news for BHBU! We're F'ed :)
     
  3. Anonymous

    Anonymous Guest

    I can make up quotes too. Where is the link?
     
  4. Anonymous

    Anonymous Guest

    The US Pharmaceuitcal/Biotech Industry is one of the most corrupt in the US. Typically people leaving the FDA get lucrative positions in the Pharm. Co's., rewarded for their support while working for the FDA. They are only second to the SEC in corruption. Both are supported by US Congressmen and senate. What does that tell you?? Long live bribery and free private jet service.

    Amgen recently hired Steve (guy who put us on REMS)! awesome!
     
  5. Anonymous

    Anonymous Guest

    BHBU reps ARE NOT going anywhere!